Abstracts tagged "Disease Activity"

Abstract Number: 798 • 2013 ACR/ARHP Annual Meeting
Targeting Ultrasound Remission In Early Rheumatoid Arthritis – Results Of The Taser Study
James Dale¹, Anne Stirling², Iain B. McInnes¹ and Duncan Porter³, ¹Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, ²Gartnavel General Hospital, Glasgow, United Kingdom, ³Rheumatology, Gartnavel General Hospital, Glasgow, United Kingdom
Background/Purpose: The TaSER study (NCT00920478) is an open label randomized clinical trial with blinded assessments of outcome. It was designed to test whether the efficacy…
Abstract Number: 219 • 2013 ACR/ARHP Annual Meeting
Contrast-Enhanced Ultrasound Of The Sovraortic Arteries: The Potential Role In Monitoring Disease Activity and Response To Treatment In Large Vessel Vasculitis
Giuseppe Germanò¹, Pierluigi Macchioni¹, Niccolò Possemato² and Carlo Salvarani³, ¹Rheumatology Service, Arcispedale S Maria Nuova, IRCCS, Reggio Emilia, Italy, ²S.C. Reumatologia, Arcispedale Santa Maria Nuova, I.R.C.C.S., Reggio Emilia, Italy, ³Rheumatology, Arcispedale S Maria Nuova-IRCCS, Reggio Emilia, Italy
Background/Purpose: promising data has been recently published about the role of contrast-enhanced ultrasound (CEU) in the diagnosis and follow up of Takayasu arteritis (TA) -1,2-…
Abstract Number: 2869 • 2013 ACR/ARHP Annual Meeting
Changes In Patient-Reported Joint Counts and Composite Indices Can Identify Flare Of Disease Activity In Recent Onset Rheumatoid Arthritis
Karen Visser¹, Susan J. Bartlett^2,3, Clifton O. Bingham III⁴, Ernest Choy⁵, Daming Lin⁶, Juan Xiong⁷, Gilles Boire⁸, Boulos Haraoui⁹, Carol A. Hitchon¹⁰, Edward Keystone¹¹, Janet E. Pope¹², J. Carter Thorne¹³, Diane Tin¹⁴ and Vivian P. Bykerk¹⁵, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Clinical Epidemiology, McGill University, Montreal, QC, Canada, ³Division of Rheumatology, Johns Hopkins University, Baltimore, MD, ⁴Division of Rheumatology, Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Section of Rheumatology, Cardiff University, Institute of Infection and Immunity, Cardiff, United Kingdom, ⁶Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁷Mount Sinai Hospital, Toronto, ON, Canada, ⁸Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁹Department of Medicine, Centre Hospitalier de l’Université de Montréal, Montréal, QC, Canada, ¹⁰Rheumatology, University of Manitoba, Winnipeg, MB, Canada, ¹¹Rebecca MacDonald Centre for Arthritis and Autoimmune Disease, University of Toronto, Toronto, ON, Canada, ¹²St Joseph Health Care, London, ON, Canada, ¹³Southlake Regional Health Centre, Newmarket, ON, Canada, ¹⁴The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ¹⁵Rheumatology, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY
Background/Purpose: Patient-reported joint counts (JCs) have been identified as core domains for assessment of flare in rheumatoid arthritis (RA).[1] To assess the responsiveness and discriminative…
Abstract Number: 2458 • 2013 ACR/ARHP Annual Meeting
Change Over Time In The Profile Of Ankylosing Spondylitis Patients Treated With Infliximab In Canadian Routine Care
Denis Choquette¹, Michael Starr², Majed M. Khraishi³, William G. Bensen⁴, Saeed A. Shaikh⁵, Jude F. Rodrigues⁶, Dalton E. Sholter⁷, Maqbool K. Sheriff⁸, Julie Vaillancourt⁹, John S. Sampalis⁹, Allen J. Lehman¹⁰, Susan M. Otawa¹⁰, Francois Nantel¹¹ and May Shawi¹², ¹Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ²Montreal General Hospital, Montreal, QC, Canada, ³Nexus Clinical Research, St John's, NF, Canada, ⁴Department of Medicine, Division of Rheumatology, Clinical Professor, McMaster University, Hamilton, ON, Canada, ⁵Medicine, McMaster University, St Catharines, ON, Canada, ⁶Rheumatology, Windsor, ON, Canada, ⁷Rheumatology Associates, Edmonton, AB, Canada, ⁸Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ⁹JSS Medical Research, Montreal, QC, Canada, ¹⁰Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹¹Janssen Inc., Toronto, ON, Canada, ¹²Medical Affairs, Janssen Canada Inc, Toronto, ON, Canada
Background/Purpose: Canadian provincial reimbursement policies in regards with infliximab coverage status have evolved in the last decade. The objective of this study was to describe…
Abstract Number: 2247 • 2013 ACR/ARHP Annual Meeting
Response To a Sleep Query On The Multi-Dimensional Health Assessment Questionnaire (MDHAQ) Is Related To Levels Of Disease Activity
Martin J. Bergman^1,2, Sapna Sangani³, Isabel Castrejón⁴ and Theodore Pincus⁴, ¹Medicine, Drexel University College of Medicine, Philadelphia, PA, ²Taylor Hospital, Ridley Park, PA, ³Medicine, Mercy Catholic Medical Center, Lansdowne, PA, ⁴Rheumatology, Rush University Medical Center, Chicago, IL
Background/Purpose: Patients with rheumatoid arthritis (RA) often report fatigue, but a possible impact of disease on sleep and/or on disease activity are poorly characterized. We…
Abstract Number: 1566 • 2013 ACR/ARHP Annual Meeting
Consensus Definition and Preliminary Validation Of a Low Disease Activity State In Systemic Lupus Erythematosus
Eric F. Morand¹, Kate Franklyn¹, Chak S. Lau², Sandra V. Navarra³, Worawit Louthrenoo⁴, Aisha Lateef⁵, Laniyati Hamijoyo⁶, Singgih Wahono⁷, Shun-Le Chen⁸, Jinou Ou⁹, Alberta Y. Hoi¹ and Mandana Nikpour¹⁰, ¹Centre for Inflammatory Diseases, Monash University, Melbourne, Australia, ²Univ Dept of Medicine, Queen Mary Hospital, Hong Kong, Hong Kong, ³University of Santo Tomas Hospital, Manila, Philippines, ⁴Dept of Internal Medicine, Faculty of Medicine, Chiang Mai, Thailand, ⁵Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore, ⁶Hasan Sadikin Hospital, Bandung, Indonesia, ⁷Universitas Brawijaya, Malang, Indonesia, ⁸Shanghai Jiao Tong University School of Medicine, Shanghai, China, ⁹3rd Hospital of Sun Yat-san University, Guang Zhou, China, ¹⁰Department of Medicine (St Vincent's Hospital), University of Melbourne, Fitzroy, Australia
Background/Purpose: The definitions of low disease activity state (LDAS) and remission as desirable treatment goals in rheumatoid arthritis have been widely applied in research and…
Abstract Number: 1352 • 2013 ACR/ARHP Annual Meeting
What Factors Lead To Achieve and Sustain Remission In Rheumatoid Arthritis Patients With Moderate To High Disease Activity?
Soo-Kyung Cho^1,2, Yoon-Kyoung Sung^1,2, Jeeseon Shim³, Chan-Bum Choi^4,5, Jung-Yoon Choe⁶, Won Tae Chung⁷, Seung-Jae Hong⁸, Jae-Bum Jun⁵, Tae-Hwan Kim⁹, Tae-Jong Kim¹⁰, Eun-Mi Koh¹¹, Jisoo Lee¹², Shin-Seok Lee¹⁰, Sung Won Lee¹³, Dae-Hyun Yoo⁵ and Sang-Cheol Bae^1,2, ¹Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ²Department of Rheumatology, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, ³Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, ⁴Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, ⁵Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ⁶Catholic University of Daegu School of Medicine, Daegu, South Korea, ⁷Division of Rheumatology, Department of Internal Medicine, Dong-A University Hospital, Busan, South Korea, ⁸Division of Rheumatology, Department of Internal Medicine, Kyung Hee University, Seoul, South Korea, ⁹Division of Rheumatology, Department of Internal Medicine, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ¹⁰Rheumatology, Chonnam National University Medical School and Hospital, Gwangju, South Korea, ¹¹Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ¹²Internal Medicine, Ewha Womans University Mokdong Hospital, Seoul, South Korea, ¹³Rheumatology, Dong-A University Hospital, Busan, South Korea
Background/Purpose: Clinical remission has now become the treatment goal in rheumatoid arthritis (RA), but it is not common in clinical practice. This study aimed to…
Abstract Number: 747 • 2013 ACR/ARHP Annual Meeting
Efficacy Of Glucocorticoids To Treat Limited Flares In ANCA-Associated Vasculitis
Eli Miloslavsky¹, Ulrich Specks², Peter A. Merkel³, Philip Seo⁴, Robert F. Spiera⁵, Carol A. Langford⁶, Gary S. Hoffman⁷, Cees G.M. Kallenberg⁸, E. William St. Clair⁹, Nadia Tchao¹⁰, Linna Ding¹¹, David Ikle¹², Brett Jepson¹², Paul Brunetta¹³ and John H. Stone¹⁴, ¹Division of Rheumatology, Massachusetts General Hopsital, Boston, MA, ²Mayo Clinic, Rochester, MN, ³Division of Rheumatology, Vasculitis Center, University of Pennsylvania, Philadelphia, PA, ⁴Rheumatology Division, Johns Hopkins Vasculitis Center, Johns Hopkins University, Baltimore, MD, ⁵Rheumatology, Hospital for Special Surgery, New York, NY, ⁶Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH, ⁷Center for Vasculitis Care and Research, Cleveland Clinic Foundation, Cleveland, OH, ⁸Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ⁹Medicine, Duke University Medical Center, Durham, NC, ¹⁰Immune Tolerance Network, Bethesda, MD, ¹¹NIAID, Bethesda, MD, ¹²Rho, Chapel Hill, NC, ¹³Biotherapeutics, Genentech, So San Francisco, CA, ¹⁴Rheumatology, Massachusetts General Hospital, Boston, MA
Background/Purpose: The great majority of patients with granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) achieve disease remission initially, but relapses occur in up to…
Abstract Number: 110 • 2013 ACR/ARHP Annual Meeting
Differing Disease Expression In Latin American Mestizo and Spanish Caucasian Patients With Rheumatoid Arthritis With The Same Access To Healthcare and Antirheumatic Treatment
Virginia Ruiz-Esquide¹, Sonia Cabrera², Julio Ramirez³, M. Victoria Hernández², José Inciarte¹, J. D. Cañete³ and Raimon Sanmarti², ¹Arthritis Unit. Rheumatology Service, Hospital Clinic of Barcelona, Barcelona, Spain, ²Arthritis Unit. Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain, ³Rheumatology, Hospital Clinic, Barcelona, Spain
Background/Purpose: Rheumatoid arthritis (RA) prevalence and clinical phenotype varies between ethnic groups. Few studies have analyzed differences in disease expression between Latin-Americans mestizos (LA) and…
Abstract Number: 2871 • 2013 ACR/ARHP Annual Meeting
Validation Of The FLARE Self-Report Questionnaire For Assessing FLARE Out Of The Clinical Visit In Rheumatoid Arthritis
Jacques Morel¹, Jean-Marie Berthelot², Arnaud L. Constantin³, Michel De Bandt⁴, Philippe Gaudin⁵, Olivier Vittecoq⁶, Jean Francis Maillefert⁷, Olivier Meyer⁸, Thao Pham⁹, Alain Saraux¹⁰, Elisabeth Solau Gervais¹¹, Elisabeth Spitz¹², Daniel Wendling¹³, Francis Guillemin¹⁴ and Bruno Fautrel¹⁵, ¹Department of Rheumatology, Hôpital Lapeyronie, Montpellier, France, ²Rheumatology Unit, Nantes University Hospital, Nantes, France, ³Rheumatology, Purpan University Hospital, Toulouse, France, ⁴Rhumatologie Et Médecine Interne, Centre hospitalier Universitaire de Fort de France, Fort de France, Martinique, ⁵Rheumatology Department, CHU Hôpital Sud, Grenoble Teaching Hospital, Echirolles, France, ⁶Rheumatology, Department of Rheumatology, Rouen University Hospital & Inserm 905, Institute for Biomedical Research, University of Rouen, Rouen, France, ⁷University Hospital, Department of Rheumatology, Dijon, France, ⁸Rheumatology, Bichat University Hospital, Paris, France, ⁹Rheumatology Department, Sainte Marguerite Hospital, Marseille, France, ¹⁰Rhumatologie, CHU de la Cavale Blanche, Brest Cedex, France, ¹¹Departement of Rheumatology, CHU de Poitiers, Poitiers, France, ¹²UFR Sciences Humaines et Arts, APEMAC-EA4360, Metz, France, ¹³Rheumatology, University Hospital, Besancon, France, ¹⁴CHU Nancy, Clinical Epidemiology and Evaluation, Université de Lorraine, Paris Descartes University, APEMAC, EA 4360, Nancy, France, ¹⁵Paris 6 – Pierre et Marie Curie University; AP-HP, Rheumatology, Pitié-Salpêtrière Hospital, - GRC-UPMC 08 – EEMOIS, Paris, France
Background/Purpose: Defining flare in rheumatoid arthritis (RA) raises a complex issue related to the difference in perception or concept of flare between patients or health…
Abstract Number: 2446 • 2013 ACR/ARHP Annual Meeting
Opiate Use In Patients With Ankylosing Spondylitis
John D. Reveille¹, Michael M. Ward², MinJae Lee³, Mohammad Rahbar⁴, Manouchehr Ardjomand-Hessabi⁵, Laura A. Diekman⁵, Matthew A. Brown⁶, Lianne S. Gensler⁷ and Michael H. Weisman⁸, ¹Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ²Bldg 10 CRC Rm 4-1339, NIAMS/NIH, Bethesda, MD, ³Medicine, University of Texas Health Science Center at Houston, Houston, TX, ⁴The University of Texas Health Science Center at Houston, Houston, TX, ⁵Rheumatology, The University of Texas Health Science Center at Houston, Houston, TX, ⁶Translational Research Institute, University of Queensland Diamantina Institute, Brisbane, Australia, ⁷Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁸Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA
Background/Purpose: Prescription opiates are commonly prescribed in patients with chronic pain, yet there is no evidence that these drugs ameliorate disease progression, and are associated with numerous…
Abstract Number: 2196 • 2013 ACR/ARHP Annual Meeting
Aberrant IgG Glycosylation Is Associated With Active Disease In Juvenile Idiopathic Arthritis Patients
Esperanza Cleland, Brooke Gilliam and Terry L. Moore, Internal Medicine/Rheumatology, Saint Louis University, Saint Louis, MO
Background/Purpose: Aberrant glycosylation of IgG is an abnormality of humoral immunity in patients with rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA) that is not…
Abstract Number: 1550 • 2013 ACR/ARHP Annual Meeting
Validation Of The Ankylosing Spondylitis Disease Activity Score and Effectiveness Of Infliximab In The Treatment Of Ankylosing Spondylitis Over 4 Years: The Canadian Experience
Proton Rahman¹, Denis Choquette², Majed M. Khraishi³, William G. Bensen⁴, Saeed A. Shaikh⁵, Dalton E. Sholter⁶, Maqbool K. Sheriff⁷, Emmanouil Rampakakis⁸, John S. Sampalis⁸, Francois Nantel⁹, Susan M. Otawa¹⁰, Allen J. Lehman¹⁰ and May Shawi¹¹, ¹Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ²Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ³Nexus Clinical Research, St John's, NF, Canada, ⁴Department of Medicine, Division of Rheumatology, Clinical Professor, McMaster University, Hamilton, ON, Canada, ⁵Medicine, McMaster University, St Catharines, ON, Canada, ⁶Rheumatology Associates, Edmonton, AB, Canada, ⁷Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ⁸JSS Medical Research, Montreal, QC, Canada, ⁹Janssen Inc., Toronto, ON, Canada, ¹⁰Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹¹Medical Affairs, Janssen Canada Inc, Toronto, ON, Canada
Background/Purpose: The efficacy of anti-TNF in the management of Ankylosing Spondylitis (AS) has been demonstrated in numerous controlled clinical trials. The objective of this study…
Abstract Number: 1322 • 2013 ACR/ARHP Annual Meeting
Osteoprotegerin and TNF-Related Apoptosis Inducing Ligand Are Respectively Predictive Factors Of Remission and Erosion In Early Rheumatoid Arthritis Patients Included In The French Cohort Espoir
Rachel Audo¹, Laura Papon¹, Claire I. Daien^1,2, Cédric Lukas³, Bernard Combe², Olivier Vittecoq⁴, Michael Hahne¹ and Jacques Morel⁵, ¹IGMM, CNRS UMR5535, Montpellier, Montpellier, France, ²Department of Rheumatology, Lapeyronie Hospital, Montpellier, France, ³Immuno-Rhumatologie, Hopital Lapeyronie, Montpellier, France, ⁴Rheumatology, Rouen University Hospital & Inserm905, University of Rouen, Rouen Cedex, France, ⁵Dpartment of Rheumatology, Lapeyronie Hospital, Montpellier, France
Background/Purpose: TNF-Related Apoptosis Inducing Ligand (TRAIL) is a member of the TNF familly. Its soluble receptor Osteoprotegerin (OPG) also inhibits Receptor activator of nuclear factor…
Abstract Number: 665 • 2013 ACR/ARHP Annual Meeting
DNA hypermethylation of Forkhead box protein 3 (FOXP3) locus leads to quantitative defects of regulatory T cells in systemic sclerosis
Yaoyao Wang¹, Ye Shu², Qing Wang¹, Ming Zhao¹, Gongping Liang¹, Qianjin Lu¹ and Rong Xiao¹, ¹Department of Dermatology, Second Xiangya Hospital, Central South University, Changsha, China, ²Department of Dermatology, Hunan Children's Hospital, Changsha, China

Background/Purpose: Systemic sclerosis (SSc) is a systemic autoimmune disease of which the etiology and pathogenesis remains complex and poorly understood. Attention has recently been directed…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].